Lyell Immunopharma, Inc.LYEL
| Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -250 | -183 | -235 | -343 |
|---|
| Acquired IPR&D expense | - | - | - | 87 |
|---|
| Impairment of long-lived assets | - | - | - | 51 |
|---|
| Stock-based compensation expense | 62 | 82 | 47 | 33 |
|---|
| Depreciation and amortization expense | 14 | 18 | 20 | 20 |
|---|
| Net amortization and accretion on marketable securities | -2 | 1 | 10 | 15 |
|---|
| Impairment of other investments | - | 5 | 13 | 13 |
|---|
| Change in fair value of contingent consideration payable | - | - | - | 4 |
|---|
| Non-cash lease income | - | - | 2 | 2 |
|---|
| Loss on property and equipment disposals, net | -1 | -0 | -2 | -1 |
|---|
| Change in fair value of success payment liabilities | 4 | -5 | -3 | -1 |
|---|
| Gain on marketable equity security | - | - | - | 0 |
|---|
| Fair Value Adjustment of Warrants | 0 | 1 | - | - |
|---|
| Gain on other investments | - | 3 | - | - |
|---|
| Prepaid expenses, other current assets and other assets | 7 | 2 | -3 | -2 |
|---|
| Accounts payable | 0 | 1 | 1 | -3 |
|---|
| Accrued liabilities and other current liabilities | 5 | -0 | -1 | -1 |
|---|
| Deferred revenue | -11 | -85 | - | - |
|---|
| Operating lease liabilities, non-current | 13 | 5 | - | - |
|---|
| Other non-current liabilities | 4 | -0 | -0 | -0 |
|---|
| Net cash used in operating activities | -126 | -170 | -164 | -162 |
|---|
| Purchases of property and equipment | 66 | 24 | 3 | 0 |
|---|
| Purchases of marketable securities | 673 | 406 | 477 | 395 |
|---|
| Maturities of marketable securities | 617 | 419 | 664 | 549 |
|---|
| Acquisition of assets, net of cash acquired | - | - | - | 31 |
|---|
| Net cash provided by (used in) investing activities | -122 | -12 | 184 | 122 |
|---|
| Proceeds from Stock Options Exercised | 9 | 10 | 0 | 0 |
|---|
| Proceeds from Stock Plans | - | 2 | 2 | 1 |
|---|
| Taxes paid related to net share settlement of equity awards | - | 0 | 0 | 0 |
|---|
| Net cash provided by financing activities | 401 | 11 | 2 | 1 |
|---|
| Net (decrease) increase in cash, cash equivalents and restricted cash | 153 | -170 | 22 | -39 |
|---|
| Cash Paid For Amounts Included In Measurement Of Lease Liabilities | 9 | 11 | 11 | 11 |
|---|
| Cash received for amounts related to tenant improvement allowances | 13 | 5 | - | - |
|---|
| Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | - | - | - | 36 |
|---|
| Contingent consideration payable | - | - | - | 11 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 5 | 1 | 0 | 0 |
|---|
| Acquisition of PACT Series D convertible preferred shares | - | 3 | - | - |
|---|
| Remeasurement of operating lease right-of-use asset for lease modification | 4 | 0 | - | - |
|---|